Is there a role of statins in the prevention of aortic biological prostheses degeneration

Cardiovascular Ultrasound

Volumn 4, Issue , 2006, Pages

  Antonini Canterin, Francesco ^a   Zuppiroli, Alfredo ^b   Baldessin, Ferdinando ^a   Popescu, Bogdan A ^c   Nicolosi, Gian Luigi ^a  

^a S MARIA DEGLI ANGELI HOSPITAL   (Italy)

^b SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^c Institute of Cardiovascular Diseases   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DODECYL SULFATE SODIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID;

AORTA ATHEROSCLEROSIS; AORTA STENOSIS; AORTA VALVE PROSTHESIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; DEGENERATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; HUMAN; HYPERCHOLESTEROLEMIA; PROPHYLAXIS; PROSTHESIS FAILURE; REVIEW; UNSPECIFIED SIDE EFFECT;

ANIMALS; AORTIC VALVE STENOSIS; ATHEROSCLEROSIS; BIOPROSTHESIS; EQUIPMENT FAILURE ANALYSIS; HEART VALVE PROSTHESIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PROSTHESIS FAILURE;

EID: 33845468802     PISSN: None     EISSN: 14767120     Source Type: Journal    
DOI: 10.1186/1476-7120-4-26     Document Type: Review

References (33)

1. Bloomfield P, Wheatley DJ, Prescott RJ, Miller HC: Twelve-year comparison of a Bjork-Shiley mechanical heart valve with porcine bioprosthesis. N Engl J Med 1991, 324:573-579.
2. Hammermeister K, Sethi GK, Henderson WG, Grover FL, Oprian C, Rahimtoola S: Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs Randomized Trial. J Am Coll Cardiol 2000, 36:1152-1158.
3. The United Kingdom Heart Valve Registry Report 1997. In UK Heart Valve Registry London: Imperial College School of Medicine, Hammersmith Hospital; 1999.
4. Treasure T: Rethink on biological aortic valves for the elderly. Lancet 1999, 354:964-965.
5. Aronow WS, Ahn C, Kronzon I, Goldman ME: Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol 2001, 88:693-695.
6. Novaro GM, Tiong IY, Pearce GL, Lauer MS, Sprecher DL, Griffin BP: Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis. Circulation 2001, 104:2205-2209.
7. Bellamy MF, Pellikka PA, Klarich KW, Tajik AJ, Enriquez-Sarano M: Association of cholesterol levels hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol 2002, 40:1723-30.
8. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O'Brien KD: Characterization of the early lesion of "degenerative" valvular aortic stenosis. Circulation 1994, 90:844-853.
9. O'Brien KD, Reichenbach DD, Marcovina SM, Kuusisto J, Alpers CE, Otto CM: Apolipoproteins B, (a), an E accumulate in the morphologically early lesion of "degenerative" valvular aortic stenosis. Atheroscler Thromb Vasc Biol 1996, 16:523-532.
10. Mohler ER 3rd: Are atherosclerotic processes involved in aortic-valve calcification? Lancet 2000, 356:524-525.
11. Agmon Y, Khandheria BK, Meissner I, Sicks JR, O'Fallon WM, Wiebers DO, Whisnant JP, Seward JB, Tajik AJ: Aortic valve sclerosis and aortic atherosclerosis: different manifestations of the same disease? Insights from a population-based study. J Am Coll Cardiol 2001, 38:827-834.
12. Rajamannan NM, Subramaniam M, Springett M, Sebo TC, Niekrasz M, McConnell JP, Singh RJ, Stone NJ, Bonow RO, Spelsberg TC: Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation 2002, 105:2660-2665.
13. Pohle K, Maffert R, Ropers D, Moshage W, Stilianakis N, Daniel WG, Achenbach S: Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation 2001, 104:1927-1932.
14. Shavelle DM, Takasu J, Budoff MJ, Mao S, Zhao XQ, O'Brien KD: HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet 2002, 359:1125-26.
15. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA, for the Scottish Aortic Stenosisand Lipid Lowering Trial Impact on Regression (SALTIRE) Investigators: A Randomized Trial of Intensive Lipid-Lowering Therapy in Calcific Aortic Stenosis. N Engl J Med 2005, 352:2389-2397.
16. Antonini-Canterin F, Popescu BA, Huang G, Korcova-Miertusova R, Rivaben D, Faggiano P, Pavan D, Piazza R, Bolis A, Ciavattone A, Ruggiero A, Nicolosi GL: Progression of aortic valve sclerosis and aortic valve stenosis: what is the role of statin treatment? Ital Heart J 2005, 6:119-124.
17. Cunanan CM, Cabiling CM, Dinh TT, Shen SH, Tran-Hata P, Rutledge JH 3rd, Fishbein MC: Tissue characterization and calcification potential of commercial bioprosthetic heart valves. Ann Thorac Surg 2001:417-421.
18. Wright JTM, Eberhardt CE, Gibbs ML, Saul T, Gilpin CB: "Hancock II-An improved bioprosthesis". In Cardiac bioprostheses. Proceedings of the 2nd International Symposium Edited by: Cohn LH, Gallucci V. Yorke Medical Books, New York; 1982:425-444.
19. Ferrans VJ, McManus B, Roberts WC: Cholesteryl ester crystals in a porcine aortic valvular bioprosthesis implanted for eight years. Chest 1983, 83:698-701.
20. Bottio T, Thiene G, Pettenazzo E, Ius P, Bortolotti U, Rizzoli G, Valfre C, Casarotto D, Valente M: Hancock II bioprosthesis: a glance at the microscope in mid-long-term explants. J Thorac Cardiovasc Surg 2003, 126:99-105.
21. Farivar RS, Cohn LH: Hypercholesterolemia is a risk factor for bioprosthetic valve calcification and explantation. J Thorac Cardiovasc Surg 2003, 126:969-976.
22. Nollert G, Miksch J, Kreuzer E, Reichart B: Risk factors for atherosclerosis and the degeneration of pericardial valves after aortic valve replacement. J Thorac Cardiovasc Surg 2003, 126:965-968.
23. David TE, Ivanov J: Is degenerative calcification of the native aortic valve similar to calcification of bioprosthetic heart valves? J Thorac Cardiovasc Surg 2003, 126:939-941.
24. Antonini-Canterin F, Zuppiroli A, Popescu BA, Granata G, Cervesato E, Piazza R, Pavan D, Nicolosi GL: Effect of statins on the progression of bioprosthetic aortic valve degeneration. Am J Cardiol 2003, 92:1479-1482.
25. Antonini-Canterin F, Popescu BA, Zuppiroli A, Nicolosi GL: Are statins effective in preventing bioprosthetic aortic valve failure? A need for a prospective, randomized trial. Ital Heart J 2004, 5:85-88.
26. Rosenhek R, Rader F, Heger M, Gabriel H, Binder T, Maurer G, Baumgartner H: Statin therapy does not affect bioprosthetic valve degeneration. J Am Coll of Cardiol 2004:433-434.
27. Skowasch D, Schrempf S, Preusse CJ, Likungu JA, Welz A, Lüderitz B, Bauriedel G: Tissue-resident C-reactive protein within degenerative aortic valves: correlation with serum CRP levels and modification by statins. Heart on line 2005. doi:10.1136/hrt.2005.069815
28. Skowasch D, Schrempf S, Wernert N, Steinmetz M, Jabs A, Tuleta I, Welsch U, Preusse CJ, Likungu JA, Welz A, Lüderitz B, Bauriedel G: Cells of primarily extravalvular origin in degenerative aortic valves and bioprostheses. Eur Heart J 2005, 26:2576-2580.
29. Farmer JA: Pleiotropic effects of statins. Curr Atheroscler Rep 2000, 2:208-217.
30. Callister TQ, Raggi P, Cooil B, Lippolis NJ, Russo DJ: Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med 1998, 339:1972-1978.
31. Wu B, Elmariah S, Kaplan FS, Cheng G, Mohler ER 3rd: Paradoxical effects of statins on aortic valve myofibroblasts and osteoblasts: implications for end-stage valvular heart disease. Arterioscler Thromb Vasc Biol 2005, 25:592-7.
32. Martinez-Gonzalez J, Badimon L: Human and porcine smooth muscle cells share similar proliferation dependence on the mevalonate pathway: implication for in vivo interventions in the porcine model. Eur J Clin Invest 1996, 26:1023-1032.
33. Martinez-Gonzalez J, Alfon J, Berrozpe M, Badimon L: HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels. Atherosclerosis 2001, 159:27-33.